Ivabradine in chronic heart failure therapy Review article
Article Sidebar
Published:
Dec 31, 2012
Keywords:
chronic heart failure, ivabradine, heart rate
Main Article Content
Abstract
High heart rate (HR) is known to be independent risk factor of cardiovascular death. In chronic heart failure and stable angina β-blockers are the first line pharmacotherapy to reduce HR, due to their adverse effects however there are rarely use in full doses. According to latest guidelines in patient with chronic heart failure, sinus rhythm and HR equal or above 70 bpm despite β-blockers usage of ivabradine should be taken into consideration. Clinical studies have shown ivabradine to reduce cardiovascular outcomes and improve life quality in chronic heart failure patients.
Article Details
How to Cite
Wełnicki , M., Adamska-Wełnicka , A., & Mamcarz , A. (2012). Ivabradine in chronic heart failure therapy. Medycyna Faktow (J EBM), 5(4(17), 69-73. Retrieved from https://journalsmededu.pl/index.php/jebm/article/view/2444
Issue
Section
Articles
Copyright © by Medical Education. All rights reserved.
References
1. McMurray J.J., Adamopoulos S., Anker S.D. et al.: ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012. Eur. Heart J. 2012 Jul; 33(14): 1787-847.
2. Grupa Robocza 2012 Europejskiego Towarzystwa Kardiologicznego (ESC) do spraw rozpoznania oraz leczenia ostrej i przewlekłej niewydolności serca działająca we współpracy z Asocjacją Niewydolności Serca ESC (HFA). Wytyczne ESC dotyczące rozpoznania oraz leczenia ostrej i przewlekłej niewydolności serca na 2012 rok. Kardiologia Polska 2012; 70(supl. II): 101-176.
3. Kasprzak J.D., Stępińska J., Wożakowska-Kapłon B. et al.: Optymalna częstość rytmu serca – aktualny cel terapii kardiologicznej Stanowisko grupy ekspertów Sekcji Farmakoterapii Sercowo-Naczyniowej Polskiego Towarzystwa Kardiologicznego. Kardiologia Polska 2012; 70(10): 1081-1094.
4. Bohm M. et al.: Ivabradine and outcomes in chronic heart failure — Authors’ reply. Lancet 2010; 376: 886-894.
5. Colin P. et al.: Effect of graded heart rate reduction with ivabradine on myocardial oxygen consumption and diastolic time in exercising dogs. J. Pharmacol. Exp. Ther. 2004; 308: 236-240.
6. Colin P. et al.: Differential effects of heart rate reduction and β-blockade on left ventricular relaxation during exercise. Am. J. Physiol. Heart Circ. Physiol. 2002, 282: H672-H679.
7. Gheorghiade M. et al.: Pathophysiologic targets in the early phase of acute heart failure syndromes. Am J. Cardiol. 2005; 96: 11G-17G.
8. Stewart S. et.al.: The current cost of heart failure to the National Health Service in the UK. Eur. J. Heart Fail. 2002; 4: 361-371.
9. Borer J.S. et al.: European Heart Journal [doi: 10.1093/eurheartj/ehs259].
10. Fox K., Garcia M.A., Ardissino D. et al.; Task force on the management of stable angina pectoris of the European Society of Cardiology; ESC Committee for Practice Guidelines (CPG). Guidelines on the management of stable angina pectoris: executive summary: the task force on the management of stable angina pectoris of the European Society of Cardiology. Eur. Heart J. 2006; 27: 1341-1381.
11. Swedberg K., Komajda M., Böhm M. et al.: Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet 2010; 376: 875-85.
12. Swedberg K., Komajda M., Böhm M. et al.: Effects on Outcomes of Heart Rate Reduction by Ivabradine in Patients With Congestive Heart Failure: Is There an Influence of Beta-Blocker Dose? Findings From the SHIFT (Systolic Heart failure treatment with the If inhibitor ivabradine Trial) Study. J. Am. Coll. Cardiol. 2012; 59(22): 1938-1945.
13. Komajda M., Böhm M., Borer J.: Influence of background treatment with mineralocorticoid receptor antagonists on ivabradine’s effects in patients with chronic heart failure. Eur. J. Heart Fail. 2012 [online: doi: 10.1093/eurjhf/hfs127].
14. Ekman I., Chassany O., Komajda M. et al.: Heart rate reduction with ivabradine and health related quality of life in patients with chronic heart failure: results from the SHIFT study. Eur. Heart J. 2011; 32: 2395-2404.
15. Böhm M., Borer J., Ford I. et al.: Heart rate at baseline influences the effect of ivabradine on cardiovascular outcomes in chronic heart failure: analysis from the SHIFT study. Clin. Res. Cardiol. 2012 [online: doi: 10.1007/s00392-012-0467-8].
2. Grupa Robocza 2012 Europejskiego Towarzystwa Kardiologicznego (ESC) do spraw rozpoznania oraz leczenia ostrej i przewlekłej niewydolności serca działająca we współpracy z Asocjacją Niewydolności Serca ESC (HFA). Wytyczne ESC dotyczące rozpoznania oraz leczenia ostrej i przewlekłej niewydolności serca na 2012 rok. Kardiologia Polska 2012; 70(supl. II): 101-176.
3. Kasprzak J.D., Stępińska J., Wożakowska-Kapłon B. et al.: Optymalna częstość rytmu serca – aktualny cel terapii kardiologicznej Stanowisko grupy ekspertów Sekcji Farmakoterapii Sercowo-Naczyniowej Polskiego Towarzystwa Kardiologicznego. Kardiologia Polska 2012; 70(10): 1081-1094.
4. Bohm M. et al.: Ivabradine and outcomes in chronic heart failure — Authors’ reply. Lancet 2010; 376: 886-894.
5. Colin P. et al.: Effect of graded heart rate reduction with ivabradine on myocardial oxygen consumption and diastolic time in exercising dogs. J. Pharmacol. Exp. Ther. 2004; 308: 236-240.
6. Colin P. et al.: Differential effects of heart rate reduction and β-blockade on left ventricular relaxation during exercise. Am. J. Physiol. Heart Circ. Physiol. 2002, 282: H672-H679.
7. Gheorghiade M. et al.: Pathophysiologic targets in the early phase of acute heart failure syndromes. Am J. Cardiol. 2005; 96: 11G-17G.
8. Stewart S. et.al.: The current cost of heart failure to the National Health Service in the UK. Eur. J. Heart Fail. 2002; 4: 361-371.
9. Borer J.S. et al.: European Heart Journal [doi: 10.1093/eurheartj/ehs259].
10. Fox K., Garcia M.A., Ardissino D. et al.; Task force on the management of stable angina pectoris of the European Society of Cardiology; ESC Committee for Practice Guidelines (CPG). Guidelines on the management of stable angina pectoris: executive summary: the task force on the management of stable angina pectoris of the European Society of Cardiology. Eur. Heart J. 2006; 27: 1341-1381.
11. Swedberg K., Komajda M., Böhm M. et al.: Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet 2010; 376: 875-85.
12. Swedberg K., Komajda M., Böhm M. et al.: Effects on Outcomes of Heart Rate Reduction by Ivabradine in Patients With Congestive Heart Failure: Is There an Influence of Beta-Blocker Dose? Findings From the SHIFT (Systolic Heart failure treatment with the If inhibitor ivabradine Trial) Study. J. Am. Coll. Cardiol. 2012; 59(22): 1938-1945.
13. Komajda M., Böhm M., Borer J.: Influence of background treatment with mineralocorticoid receptor antagonists on ivabradine’s effects in patients with chronic heart failure. Eur. J. Heart Fail. 2012 [online: doi: 10.1093/eurjhf/hfs127].
14. Ekman I., Chassany O., Komajda M. et al.: Heart rate reduction with ivabradine and health related quality of life in patients with chronic heart failure: results from the SHIFT study. Eur. Heart J. 2011; 32: 2395-2404.
15. Böhm M., Borer J., Ford I. et al.: Heart rate at baseline influences the effect of ivabradine on cardiovascular outcomes in chronic heart failure: analysis from the SHIFT study. Clin. Res. Cardiol. 2012 [online: doi: 10.1007/s00392-012-0467-8].